Package Leaflet: Information for the User
Fluad injectable suspension in a pre-filled syringe
Influenza vaccine (surface antigen, inactivated, with adjuvant)
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the package leaflet
Fluad is an influenza vaccine.
When a person is given the vaccine, the immune system (the body's natural defense system) will produce its own protection against the influenza virus. None of the components of the vaccine can cause influenza.
Fluad is used to prevent influenza in people aged 50 years and over.
The vaccine is aimed at the strains of the influenza virus following the recommendations of the World Health Organization for the 2025/2026 campaign.
You should not be given Fluad
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you are given Fluad.
BEFORE vaccination
As with all vaccines, Fluad may not completely protect all people who are vaccinated.
Children
Fluad is not recommended for use in children.
Other medicines and Fluad
Tell your doctor or nurse if you are using, have recently used, or might use any other medicines, including those obtained without a prescription, or if you have recently received any other vaccine.
Pregnancy and breastfeeding
This vaccine is intended for adults aged 50 years and over. It should not be used in women who are or may be pregnant, or during breastfeeding.
Driving and using machines
Fluad has no or negligible influence on the ability to drive and use machines.
Fluad contains potassium and sodium
This vaccine contains less than 1 mmol of sodium (23 mg) per dose; this is, essentially "sodium-free".
This vaccine contains potassium, less than 1 mmol (39 mg) per dose; this is, essentially "potassium-free".
Your doctor or nurse will give you Fluad as an injection into the muscle of the upper arm (deltoid muscle).
Adults aged 50 years and over:
A dose of 0.5 ml
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or go to the emergency department of your nearest hospital immediately if you experience the following serious side effects, as you may need urgent medical attention or hospitalization:
The following side effects have been reported during clinical trials in adults aged 50 years and over.
Very common (may affect more than 1 in 10 people):
1 Reported as frequent in elderly subjects aged 65 years and over.
Common (may affect up to 1 in 10 people):
2 Reported in elderly subjects aged 65 years and over.
3 Reported as uncommon in elderly subjects aged 65 years and over.
Uncommon (may affect up to 1 in 100 people):
Most side effects were mild or moderate and disappeared within 3 days of onset.
In addition to the side effects mentioned, the following side effects have occasionally occurred during general use of the quadrivalent influenza vaccine or Fluad.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that the side effects are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in a refrigerator (between 2 °C and 8 °C). Do not freeze. Discard if the vaccine has been frozen. Keep the pre-filled syringe in the outer packaging to protect it from light.
Do not use this vaccine after the expiry date which is stated on the label and on the carton after EXP/CAD. The expiry date is the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Fluad
Per 0.5 ml dose | |
Strain similar to A/Victoria/4897/2022 (H1N1)pdm09 (A/Victoria/4897/2022, IVR-238) | 15 micrograms HA** |
Strain similar to A/Croatia/10136RV/2023 (H3N2) (A/Croatia/10136RV/2023, X-425A) | 15 micrograms HA** |
Strain similar to B/Austria/1359417/2021 (B/Austria/1359417/2021, BVR-26) | 15 micrograms HA** |
*propagated in embryonated chicken eggs from healthy chicken flocks and adjuvanted with MF59C.1
**hemagglutinin
This vaccine complies with the recommendation of the World Health Organization (WHO) (northern hemisphere) and with the EU recommendation for the 2025/2026 season.
Appearance of the product and pack contents
Fluad is an injectable suspension in a pre-filled syringe. Fluad is a white, cloudy suspension. Each pre-filled syringe contains a single dose (0.5 ml) of injectable suspension. Fluad is available in packs containing 1 or 10 pre-filled syringes with or without needles.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Seqirus Netherlands B.V.
Paasheuvelweg 28, 1105 BJ Amsterdam, Netherlands
For further information about this medicine, contact the local representative of the marketing authorisation holder:
Belgium/Belgique/Belgien Seqirus Netherlands B.V.Nederland/Netherlands Tel: +31 (0) 20 204 6900 | Lithuania Seqirus Netherlands B.V. Nyderlandai Tel: +31 (0) 20 204 6900 |
Luxembourg/Luxemburg Seqirus Netherlands B.V. Netherlands Tél/Tel: +31 (0) 20 204 6900 | |
Czech Republic Seqirus Netherlands B.V. Nizozemsko Tel: +31 (0) 20 204 6900 | Hungary Seqirus Netherlands B.V. Hollandia Tel.: +31 (0) 20 204 6900 |
Denmark Seqirus Netherlands B.V. Holland Tlf: +31 (0) 20 204 6900 | Malta Seqirus Netherlands B.V. In-Netherlands Tel: +31 (0) 20 204 6900 |
Germany Seqirus GmbH Marburg Tel: 0800/3601010 | Netherlands Seqirus Netherlands B.V. Amsterdam Tel: +31 (0) 20 204 6900 |
Estonia Seqirus Netherlands B.V. Holland Tel: +31 (0) 20 204 6900 | Norway Seqirus Netherlands B.V. Nederland Tlf: +31 (0) 20 204 6900 |
Austria Valneva Austria GmbH, Wien Tel: +43 1 20620 2020 | |
Spain Seqirus Spain S.L. Barcelona Tel 937 817 884 | Poland Seqirus Netherlands B.V. Holandia Tel.: +31 (0) 20 204 6900 |
France Seqirus Netherlands B.V. Netherlands Tél: +31 (0) 20 204 6900 | Portugal Seqirus Netherlands B.V. Países Baixos Tel: +31 (0) 20 204 6900 |
Croatia Seqirus Netherlands B.V. Nizozemska Tel: +31 (0) 20 204 6900 | Romania Seqirus Netherlands B.V. Olanda Tel: +31 (0) 20 204 6900 |
Ireland Seqirus UK Limited Maidenhead Tel: +44 1628 641 500 | Slovenia Seqirus Netherlands B.V. Nizozemska Tel: +31 (0) 20 204 6900 |
Iceland Seqirus Netherlands B.V. Holland Sími: +31 (0) 20 204 6900 | Slovakia Seqirus Netherlands B.V. Holandsko Tel: +31 (0) 20 204 6900 |
Italy Seqirus S.r.l. Siena Tel: +39 0577 096400 | Finland Seqirus Netherlands B.V. Alankomaat Puh/Tel: +31 (0) 20 204 6900 |
Sweden Seqirus Netherlands B.V. Nederländerna Tel: +31 (0) 20 204 6900 | |
Latvia Seqirus Netherlands B.V. Niderlande Tel: +31 (0) 20 204 6900 |
Date of last revision of this leaflet: 07/2025.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
-----------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Medical treatment and adequate supervision should always be readily available in case of an anaphylactic episode, which can rarely occur after vaccine administration.
Shake gently before use. After shaking, the normal appearance of the vaccine is a white, cloudy suspension.
The vaccine should be inspected visually for particulate matter and color changes before administration. If particulate matter and/or any variation of the physical appearance is observed, do not administer the vaccine.
If a pre-filled syringe without a needle is used, the protective cap should be removed from the tip of the syringe and a needle should be attached for administration. A sterile needle of suitable size should be used for intramuscular injection. For LuerLock syringes, remove the protective cap from the tip of the syringe by unscrewing it in an anticlockwise direction. Once the protective cap has been removed, attach a needle to the syringe by screwing it in a clockwise direction until it is secure. When the needle is securely in place, remove the needle protector and administer the vaccine.